Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Wegovy (semaglutide) — Summary of Product Characteristics

European Medicines Agency. EMA European Public Assessment Report 2024

Document identifier
CEI-BR-019
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
European Medicines Agency
Title
Wegovy (semaglutide) — Summary of Product Characteristics
Source
EMA European Public Assessment Report
Year
2024
Volume, issue, pages
EMEA/H/C/005422
Digital object identifier
not held by the Institute
PubMed identifier
not held by the Institute
Record type
Regulatory document
Institute identifier
CEI-BR-019

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: SemaglutideCompound monograph
1 citing document.

§1.3Subject tags

semaglutide label ema

Compound Evidence Institute · CEI-BR-019 · https://compoundevidence.com/bibliography/emawegovy/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.